What’s Propelling GlycoMimetics, Inc. (GLYC) to Increase So Much?

Investors sentiment increased to 1.32 in 2019 Q1. Its up 0.26, from 1.06 in 2018Q4. It is positive, as 7 investors sold GlycoMimetics, Inc. shares while 21 reduced holdings. 10 funds opened positions while 27 raised stakes. 44.56 million shares or 0.36% more from 44.40 million shares in 2018Q4 were reported.
Ny State Common Retirement Fund holds 0% in GlycoMimetics, Inc. (NASDAQ:GLYC) or 37,300 shares. Prelude Cap Limited Liability Corporation holds 17,604 shares. Natl Bank Of America De has 28,229 shares for 0% of their portfolio. Price T Rowe Inc Md holds 0.01% or 3.42M shares. Nea Management Ltd Liability invested in 5.88% or 9.09 million shares. Morgan Stanley reported 6,625 shares stake. Weiss Multi owns 10,000 shares or 0% of their US portfolio. Metropolitan Life Ins reported 6,330 shares or 0% of all its holdings. Axa reported 925,144 shares. Northern, a Illinois-based fund reported 459,360 shares. Tci Wealth Advsrs holds 100 shares. Citadel Limited Company owns 738,665 shares or 0% of their US portfolio. Geode Capital Mngmt Lc, a Massachusetts-based fund reported 445,076 shares. Fmr Ltd Llc invested 0.01% in GlycoMimetics, Inc. (NASDAQ:GLYC). State Street reported 0% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC).

The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) is a huge mover today! The stock increased 4.81% or $0.14 during the last trading session, reaching $3.05. About 1.71 million shares traded or 113.04% up from the average. GlycoMimetics, Inc. (NASDAQ:GLYC) has declined 32.63% since August 15, 2018 and is downtrending. It has underperformed by 32.63% the S&P500.
The move comes after 5 months positive chart setup for the $131.74M company. It was reported on Aug, 15 by Barchart.com. We have $3.17 PT which if reached, will make NASDAQ:GLYC worth $5.27M more.

GlycoMimetics, Inc. (NASDAQ:GLYC) Ratings Coverage

Among 3 analysts covering GlycoMimetics (NASDAQ:GLYC), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. GlycoMimetics has $23 highest and $500 lowest target. $11.33’s average target is 271.48% above currents $3.05 stock price. GlycoMimetics had 9 analyst reports since February 28, 2019 according to SRatingsIntel. H.C. Wainwright maintained GlycoMimetics, Inc. (NASDAQ:GLYC) on Thursday, March 7 with “Buy” rating. SunTrust downgraded GlycoMimetics, Inc. (NASDAQ:GLYC) on Monday, August 5 to “Hold” rating. As per Monday, August 5, the company rating was downgraded by Piper Jaffray.

More notable recent GlycoMimetics, Inc. (NASDAQ:GLYC) news were published by: Nasdaq.com which released: “Mid-Morning Market Update: Markets Open Lower; Tyson Foods Earnings Top Views – Nasdaq” on August 05, 2019, also Seekingalpha.com with their article: “Global Blood Therapeutics: A Promising Biotech Pick In 2019 – Seeking Alpha” published on July 29, 2019, Seekingalpha.com published: “GlycoMimetics: Forecasting The Clinical Binary For Rivipansel – Seeking Alpha” on March 29, 2019. More interesting news about GlycoMimetics, Inc. (NASDAQ:GLYC) were released by: Nasdaq.com and their article: “Pre-Market Most Active for Aug 5, 2019 : TVIX, GLYC, AMD, QQQ, TQQQ, SQQQ, TOT, BHP, BABA, NIO, NOK, APHA – Nasdaq” published on August 05, 2019 as well as Schaeffersresearch.com‘s news article titled: “GLYC Stock Sliced in Half on Disappointing Drug Data – Schaeffers Research” with publication date: August 05, 2019.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $131.74 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

GlycoMimetics, Inc. (NASDAQ:GLYC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.